Get started
Author

Anders K.M. Jakobsen

Observed names: A Jakobsen, A.K. Jakobsen
ORCID: 0009-0003-3171-9683
Observed ORCID: 0009-0003-3171-9683
OpenAlex ID: A5071460509
The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al. · Clinical Cancer Research · 15
Multiplex methylation marker analysis for ctDNA detection in liquid biopsies from anal cancer patients: an HPV-independent approach
2026 · Søren Kahns, Luisa M.D. Canto, et al. · Clinica Chimica Acta
Data from The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al.
Supplementary Figure S4 from The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al.
REMARK checklist S1 from The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al.
Supplementary Figure S1 from The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al.
Supplementary Figure S3 from The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al.
Supplementary Figure S2 from The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al.
Supplementary Figure S7 from The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al.
Supplementary Methods S1 from The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al.
Supplementary Figure S6 from The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al.
Supplementary Table S2 from The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al.
Supplementary Figure S5 from The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al.
Supplementary Table S1 from The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST
2025 · Mette M. Steiniche, Sidsel C. Lindgaard, et al.
861TiP The ctDNA-RECIST trial part one: ctDNA guided palliative systemic therapy compared to standard care in metastatic cancer - The randomised ctDNA-RECIST trial (NCT06562348)
2025 · K-L.G. Spindler, T.F. Hansen, et al. · Annals of Oncology
286P Clinical significance of ctDNA conversion during systemic therapy in metastatic pancreatic cancer: Insights from ctDNA-RECIST
2025 · M.M. Steiniche, S.C. Lindgaard, et al. · Annals of Oncology
PDF
94P A one-tube multiplex methylation-specific droplet digital PCR assay for identification of ctDNA biomarkers in anal squamous cell carcinoma
2024 · K-L. Spindler, S. Kahns, et al. · Annals of Oncology
Detection of lung cancer using a single blood biomarker and tobacco history in a high risk cohort
2022 · M Borg, L Nederby, et al. · European Respiratory Journal
Works count: 18
Citation count: 15
H-index: 1
I10-index: 1
Year
Topic
Type